A partnership between CHOC and Masimo has developed technology to noninvasively monitor blood oxygen and hemoglobin levels in newborns.
CHOC helps develop innovative treatment protocols for PTCL and NK/T-cell lymphoma, which are now available for patients.
The Inaugural CHOC and UCI Rare Disease Symposium & Family Conference will take place on Friday, March 11, 2022, from 10:30 a.m. to 3 p.m.
This study is one of the first to stratify injury severity based on the type of surgical treatment required.
The study will examine biochemical markers in the blood of children with Down syndrome for a likelihood of them developing Alzheimer’s disease in adulthood.
CHOC’s chief intelligence and innovation officer, Dr. Chang, works to develop uses of artificial intelligence (AI) to improve healthcare.